This would represent roughly 5% share in the global oncology drug market in 2026. In this note we discuss the potential upside to Merck’s earnings and share price if Keytruda were to capture an incremental 5% share in the oncology drugs market by 2026. We have created an interactive dashboard analysis ~ What’s The Upside For Merck If Keytruda Garners An Additional 5% Share of The Oncology Drug Market By 2026? How Big Is The Global Oncology Drug Market? What Will Be The Impact of Higher Keytruda Sales On Merck’s Earnings & Share Price?

Source: Forbes March 12, 2019 15:11 UTC